• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes

May 12, 2022 By Sean Whooley

Abbott Xience Skypoint
[Image from Abbott]
Abbott (NYSE:ABT) announced today that its Xience Skypoint drug-eluting stent platform is now available globally.

Xience Skypoint has received FDA approval, the CE mark, and PMDA approval in Japan for the broadest expansion with the availability of extended sizes of 4.5 mm and 5 mm offerings.

According to Abbott, Xience Skypoint stents are now the only drug-eluting stents (DES) approved in the U.S. that improve access to care, enabling physicians to deliver advanced technology to patients with larger blood vessels. The expanded sizes are high bleeding risk (HBR)-indicated and represent the only DES with both one-month and three-month dual antiplatelet therapy (DAPT) labeling.

“I’m happy to see the expansion of the Xience Skypoint size matrix to now accommodate large vessels,” Mount Sinai Queens and Mount Sinai Hospital physician Dr. George Dangas said, according to Abbott. “This was a mid-lesion in a left coronary artery of a 48-year-old male patient. The 5.0×28 delivered like a 2.5 would have and I was happy with how it accommodated the vessel tapering, with our ability to follow up post dilatation of 5.5 proximally. Good addition to the Xience family.”

Xience Skypoint received FDA approval and CE marking in July 2021. It is described by Abbott as easier to place while allowing physicians to treat larger blood vessels through improved stent expansion that can open clogged vessels more effectively.

Following FDA approval for one-month DAPT labeling using the Xience family of stents, Abbott CMO and Divisional VP of Global Medical Affairs for its vascular business Dr. Nick West, told Drug Delivery Business News that the latest iteration of the Xience platform offers a level of treatment that’s second to none.

“The Xience drug-eluting stent platform is probably the class-leading, best-in-class drug-eluting stent,” West said. “It has an unrivaled quantity and quality of data behind it. Compared to any other platform — and I’m not just saying this as a promotional thing — we have an unrivaled quantity of data. More than that, we have up to the minute data.”

Filed Under: Auto-injectors, Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Vascular Tagged With: abbott

IN CASE YOU MISSED IT

  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
  • ApiJect picks up $111M investment from Royalty Pharma, Jefferies
  • FDA approves IND for Ananda Scientific’s PTSD treatment with liquid structure delivery tech
  • Medtronic’s Resolute Onyx drug-eluting stent demonstrates strong safety, efficacy
  • Jabil launches Qfinity reusable auto-injector

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS